A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease
A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.
Inclusion Criteria:
OR
Exclusion Criteria:
Guangzhou, Guangdong 510280, China
Haerbin, Heilongjiang 150036, China
Wuhan, Hubei 430022, China
Wuhan, Hubei 430030, China
Dalian, Liaoning 116000, China
Shanghai, Shanghai Municipality 200092, China
Chengdu, Sichuan 610031, China
Hangzhou, Zhejiang 310016, China